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NK/T-cell ratios predict disease activity in relapsing remitting multiple sclerosis (RRMS). We investigated in 50 
RRMS patients whether interleukin-2 receptor alpha-chain (IL-2Rα) expression and shedding associates with NK/ 
T-cell balance, as suggested by daclizumab-trials in RRMS. A subsample (N = 31) was genotyped for IL2RA- 
associated MS risk SNPs. CD56bright NK-cell/IL-17A+CD4+ T-cell ratios correlated negatively with plasma and 
PBMC-culture supernatant sIL-2Rα-levels [R = -0.209; p = 0.038 and R = -0.254; p = 0.012, resp.], and with 
CD4+ T-cell CD25 MFI [R = -0.341; p = 0.001]. Carriers of the rs3118470 risk-allele showed higher sIL-2Rα- 
levels (P = 0.031) and a lower CD56bright NK-cell/IL-17A+CD4+ T-cell ratio (P = 0.038). Therefore, IL-2Rα may 
be involved in the interplay between NK-cells and T-cells.   
1. Introduction 
Multiple sclerosis (MS) is an immune-mediated inflammatory disease 
of the central nervous system.(Dobson and Giovannoni, 2019) Although 
not fully elucidated, many factors and pathways have been suggested to 
be relevant for MS disease activity. One of these pathways is the 
interleukin-2 (IL-2) / interleukin-2 receptor (IL-2R) pathway.(Carrieri 
et al., 1992; Sorensen, 2005) IL-2 is a cytokine with both pro- and anti- 
inflammatory effects on the immune system, well known as a survival 
cytokine for activated T cells, but also as important in the biology of 
regulatory T (Treg) cells and natural killer (NK) cells.(Gaffen and Liu, 
2004) The composition of the IL-2R is variable. Incorporation of the 
α-chain (IL-2Rα, CD25) into a tri-molecular complex renders a receptor 
with high affinity for IL-2.(Damoiseaux, 2020) Activated immune cells 
may shed IL-2Rα and produce soluble IL-2Rα (sIL-2Rα), of which higher 
circulating levels are associated with MS disease activity.(Sharief and 
Thompson, 1993) Whether sIL-2Rα by itself has a more pro- or anti- 
inflammatory role, remains controversial.(Damoiseaux, 2020) 
The IL-2/IL-2R pathway in MS gained renewed interest after the 
positive clinical results from an anti-CD25 therapy (daclizumab), aimed 
at reducing disease activity in relapsing remitting (RR)MS patients. 
(Giovannoni et al., 2014; Gold et al., 2013) Daclizumab was shown to 
increase the NK cell population, specifically the immune-regulatory 
CD56bright NK cell population, which is thought to kill activated T 
cells.(Elkins et al., 2015) This finding revealed the relevance of the 
interplay between NK and T cells in RRMS, with the IL-2R as possible 
mediator. Recently, we have shown in interferon beta-treated RRMS 
patients that disease activity is associated with lower NK/T-cell ratios, 
(Mimpen et al., 2020) which not only points towards an interesting 
potential prognostic biomarker for disease activity, but also further 
implicates an influential role of NK/T-cell interplay in RRMS. The role of 
IL-2Rα in these associations has not been explored previously. 
We studied the association between sIL-2Rα and NK/T cell ratios in 
MS. To further consolidate our finding, we extended this analysis by 
exploring several other IL-2R related markers, as well as the genetic 
status of our participants with regard to two known IL2RA-associated 
MS risk alleles. 
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2. Methods and materials 
2.1. Patients 
This study is a post-hoc extended analysis of the SOLARIUM study, 
which was a sub-study of the SOLAR study. The SOLAR study evaluated 
disease activity in interferon beta-treated RRMS patients using high dose 
vitamin D3 supplements compared to placebo. The SOLARIUM study 
investigated the effect of high dose vitamin D3 supplementations on the 
immune system composition. In- and exclusion criteria for the SOLAR 
and SOLARIUM studies are described elsewhere.(Hupperts et al., 2019; 
Muris et al., 2016) For inclusion in this analysis, all 50 participants of 
whom data regarding NK cells, T cells and IL-2Rα were available were 
included. Retrospectively, 31 of these 50 participants provided consent 
for genetic analysis. Written informed consent was acquired and the 
SOLARIUM study was approved by the Ethical Committee METC-Z (11- 
T-03; Heerlen, the Netherlands). 
2.2. PBMC isolation 
The acquirement and analysis of peripheral blood mononuclear cells 
(PBMCs) is described elsewhere.(Muris et al., 2016) In summary, pe-
ripheral blood samples were collected from patients at baseline and at 
week 48 of treatment. Blood was collected in a 10 mL sodium heparin 
blood sampling tube (BD Biosciences, Breda, The Netherlands) and 
transported to Maastricht University Medical Center, the Netherlands, at 
room temperature. Within 24 h PBMCs were isolated as described 
previously. 
2.3. IL-2 receptor alpha-chain gene expression, protein expression and 
shedding 
Measurement of sIL-2Rα is described elsewhere.(Rolf et al., 2018) In 
short, sIL-2Rα levels in plasma were measured by a chemiluminescent 
assay, using a commercially available kit for quantative measurement of 
sIL-2Rα on the Immulite 2000 (Siemens; 95% reference range 158–623 
U/mL; N = 50). Additionally, sIL-2Rα was measured in culture super-
natant of PBMCs (100,000/well) which were cultured and stimulated by 
phytohaemagglutinin (PHA; 25 μg/mL) for 72 h (N = 50). In addition, 
the process of obtaining gene expression data by PCR (N = 39) and 
staining of PBMC for flow cytometry is described elsewhere.(Muris et al., 
2016; Rolf et al., 2018) Flow cytometry was used to obtain MFI values of 
IL-2Rα (CD25) on CD4+ T cells (N = 50). The gating strategy is shown in 
Fig. 1A. Genotyping the polymorphisms rs2104286 and rs3118470 was 
done using extracted DNA from buffy coats. This DNA was analysed on 
the Infinium PsychArray-24v1.3_A1 BeadChip (Infinium array technol-
ogy) and the polymorphisms of interest were defined (N = 31). 
2.4. Statistical analysis 
SPSS software (IBM SPSS, version 25.0. Chicago, IL) was used to 
assess the correlation between baseline and week 48 IL-2Rα markers, as 
well as the correlation between IL-2Rα markers and NK/T ratios. 
Normality of data was assessed by visual inspection of histograms with 
normal curves, skewness and kurtosis. Both correlations between base-
line and week 48 IL-2Rα markers, and IL-2R markers and NK/T ratios 
were performed using a Pearson r correlation or Spearman rho corre-
lation test, depending on distribution of data. Differences in continuous 
variables between carriers of genetic risk-alleles were analysed with a 
Mann Whitney U test. A p-value of <0.05 was considered statistically 
significant. 
3. Results 
3.1. Strong correlation between baseline and week 48 plasma sIL-2Rα 
levels 
We analysed data on serum sIL-2Rα levels, supernatant sIL-2Rα 
levels, IL2RA gene expression and CD4+ T cell IL-2Rα protein expression 
at baseline and at 48 weeks follow-up (Fig. 1). While sIL-2Rα levels in 
serum at baseline and week 48 correlated strongly (R = 0.836; p 
≤0.001), other IL-2Rα related markers showed relatively low or statis-
tically non-significant correlations (Fig. 1B). Since these variables all 
show a biological variability, which also applies to the NK/T-cell ratios, 
we pooled our data of both time points. 
3.2. Lower NK/T cell ratios associate with higher IL-2Rα protein 
expression and shedding 
As NK/IL-17A+CD4+ T cell ratios were most strongly associated with 
disease activity in our previous work,(Mimpen et al., 2020) and IL-17+ T 
cells have been proposed as a pathogenic T cell subset in MS,(Li et al., 
2017) this ratio was focus for our IL-2Rα related analyses. We included 
ratios of the total, CD56bright and CD56dim NK cell subsets, to explore 
effects of these different subsets. 
Most notably, all ratios involving IL-17A+CD4+ T cells showed a 
negative correlation with serum sIL-2Rα levels (Fig. 2A), as well as sIL- 
2Rα shedding by PHA-stimulated PBMCs (Fig. 2B). Since sIL-2Rα has 
been hypothesized to be mostly shedded by activated CD4+ T cells, 
(Brusko et al., 2009) we also explored the correlation of NK/T-cell ratios 
with CD4+ T cell IL-2Rα (CD25) MFI. Although IL-2Rα MFI on Treg 
CD4+ cells did not correlate with NK/T-cell ratios (Fig. 2C), IL-2Rα MFI 
on non-Treg CD4+ T cells correlated negatively with all NK/T-cell ratios 
investigated (Fig. 2D). IL2RA gene expression levels in total PBMCs were 
available but did not correlate with NK/T-cell ratios (Fig. 2E). We 
conclude that in MS, IL-2Rα protein expression and shedding by T cells 
correlate consistently with a, relative to NK cells, increased proportion 
of circulating (pathogenic) CD4+ T cells. 
3.3. Presence of risk allele of rs3118470 is linked with higher sIL-2Rα 
levels 
To further consolidate the association of IL-2Rα related endpoints 
with NK/T-cell ratios, we genotyped a subset of participants for IL2RA- 
associated MS risk SNPs rs2104286 and rs3118470.(International Mul-
tiple Sclerosis Genetics C, 2019) Notably, the rs2104286 risk-allele has 
been associated with higher serum sIL-2Rα levels in MS.(Buhelt et al., 
2017) Of the N = 31 participants of whom genetic data were available, 
N = 30 were carriers of the rs2104286 risk allele. Comparing carriers 
and non-carries of the rs3118470 MS risk allele (N = 13 and N = 18, 
respectively), carriers had a significantly higher level of sIL-2Rα at 
baseline (Fig. 3A), as well as a lower CD56bright NK/IL-17A+CD4+ T cell 
ratio (Fig. 3C), with differences between other NK/T-cell ratios not 
being statistically significant (Fig. 3B and D). 
4. Discussion 
We investigated the role of IL-2Rα in the interplay between NK and T 
cells in a cohort study using a homogenous group of interferon beta- 
treated RRMS patients. We report associations between NK/IL- 
17A+CD4+ T cell ratios and sIL-2Rα protein shedding in vivo and in 
vitro, and IL-2Rα protein expression by non-regulatory CD4+ T cells. 
Furthermore, higher baseline serum sIL-2Rα levels and lower 
CD56bright/IL-17A+CD4+ T cell ratios associate with the rs3118470 risk 
allele. 
Our results may be interpreted in different ways. First, a higher sIL- 
2Rα level may simply be the result of a lower NK/ T cell ratio. As a lower 
ratio would imply a reduced regulation of activated T cells by NK cells, 
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Fig. 1. A: Gating strategy used to analyse NK cells, T cells and their respective subsets. Step 1 shows the gating of lymphocytes from the PBMC population. Step 2 
shows the gating of NK cells, defined as CD3− NKp46+, from the lymphocyte population. Step 3 shows the differentiation between the CD56dimCD16+ NK cells 
(above) and CD56brightCD16− NK cells (below). Step 4 shows the gating of CD4+T cells, defined as CD3+CD4+, from the lymphocyte population. Step 5 shows the 
differentiation between regulatory T cells (Treg), defined as CD25+CD127− and other CD4+ T cells (nonTreg). FSC: forward scatter; SSC: side scatter. B: Correlations 
between baseline and week 48 values of soluble IL-2 receptor alpha-chain (sIL2Rα) in serum, sIL2Rα in PBMC PHA culture, IL2RA gene expression, IL-2Rα MFI on 
Tregs and IL-2Rα MFI on nonTregs. R and p-value shown are based on Spearman rho analyses. MFI: mean fluorescence index; Treg: regulatory T cell; PHA: 
phytohaemagglutinin. 
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Fig. 2. Correlations between NK/IL-17A+CD4+ T cells ratio, CD56bright NK/IL-17A+CD4+ T cells ratio and CD56dim NK/IL-17A+CD4+ T cells ratio, and A: soluble IL- 
2 receptor alpha-chain (sIL2Rα) in serum. B: soluble IL-2 receptor alpha-chain (sIL2Rα) in stimulated culture. C: IL2RA gene expression. D: IL-2 receptor alpha-chain 
expression on regulatory T cells. E: IL-2 receptor alpha-chain expression on non-regulatory CD4+ T cells. R and p-value shown are based on spearman rho analyses. 
Baseline and week 48 values are pooled. Baseline values are represented by black dots, week 48 values are represented by open dots. MFI; mean fluorescence index; 
sIL2Rα: soluble IL-2 receptor alpha-chain; Treg: regulatory T cell. 
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this would mean that there are more activated non-regulatory T cells to 
shed IL-2Rα and thus increase sIL-2Rα levels. In this scenario, sIL-2Rα 
would be a biomarker of higher T cell activity, causing disease activity, 
which could then also be expressed as a lower NK/T cell ratio. Alter-
natively, sIL-2Rα could influence NK cells and/or T cells in such a way 
that the NK/T ratio is altered, thus leading to a reduced regulation of 
activated T cells and paving the way for disease activity. Unfortunately, 
interpretation of our results is hindered by the poor understanding of the 
role of sIL-2Rα in immune activation and regulation.(Damoiseaux, 
2020) Although our genetic data does not favour one interpretation over 
the other, it does further strengthen the implication that IL-2Rα is 
involved in NK/T interplay. 
This study has some limitations. The initial research question of the 
SOLARIUM study was focused on vitamin D3 supplementation, which 
makes the current analysis exploratory. Additionally, only a limited set 
of IL-2/IL-2R pathway-related variables was explored, with IL-2 levels 
lacking. Finally, our cohort consists of patients using interferon beta, 
that transiently affects IL-2Rα expression on CD4+ T cells, which may 
have influenced our results.(Ferrarini et al., 1998) 
In conclusion, we report a significant association between IL-2Rα 
protein expression and shedding and the interplay between NK cells and 
T cells. The exact context and influence remain to be elucidated and, as 
such, more research is needed to investigate the exact mechanism of 
action in MS. 
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